Ot­su­ka to ac­quire psy­che­del­ic drug dis­cov­ery out­fit Mind­set Phar­ma

Ot­su­ka an­nounced plans to ac­quire Mind­set Phar­ma in a deal that po­si­tions the Japan­ese phar­ma in the psy­che­del­ic drug dis­cov­ery space.

Ot­su­ka is pay­ing CAN 80 mil­lion, or $59.1 mil­lion, in cash to buy the Cana­di­an de­vel­op­er of psy­che­del­ic med­i­cines that aim to treat neu­ro­log­i­cal and psy­chi­atric dis­or­ders. Mind­set’s pri­ma­ry as­set, MSP-1014, is a psilo­cy­bin-like con­ju­gate aim­ing to treat ma­jor de­pres­sive dis­or­der, or MDD. The UK in June ap­proved a Phase II tri­al for the drug.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER